sarpogrelate has been researched along with mdl 100907 in 46 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 25 (54.35) | 29.6817 |
| 2010's | 18 (39.13) | 24.3611 |
| 2020's | 3 (6.52) | 2.80 |
| Authors | Studies |
|---|---|
| Hironaka, E; Hongo, M; Kinoshita, O; Mawatari, E; Okumura, N; Sakai, A; Terasawa, F; Ushiyama, Y; Yamazaki, A; Yazaki, Y | 1 |
| Fujiwara, H; Horibe, E; Minatoguchi, S; Nishigaki, K | 1 |
| Arneja, AS; Dhalla, NS; Goyal, RK; Kumamoto, H; Saini, HK; Takeda, N | 1 |
| Asanuma, H; Fujita, M; Hirata, A; Hori, M; Kitakaze, M; Minamino, T; Node, K; Ogita, H; Okada, K; Sanada, S; Takashima, S; Tomoike, H; Tsukamoto, O | 1 |
| Hashimoto, T; Kanayama, M; Oha, F; Shigenobu, K; Yamane, S | 1 |
| Nishiyama, T | 2 |
| Ando, H; Hasegawa, T; Hotta, Y; Ishikawa, N; Miki, Y; Miyazeki, K; Muto, T; Sugimoto, Y; Yamada, J | 1 |
| Fujii, H; Hirai, T; Nishio, H; Nitanda, A; Tokumo, K; Yasunami, N | 1 |
| Iwasaka, T; Nishikawa, M; Nomura, S; Omoto, S; Shouzu, A | 1 |
| Ozaki, Y; Satoh, K; Yatomi, Y | 1 |
| Goto, F; Kawahara, K; Obata, H; Saito, S; Sasaki, M | 1 |
| Arita, K; Jawien, A; Mátyás, L; Norgren, L; Riegerd, H | 1 |
| Bhuiyan, MA; Ishiguro, M; Muntasir, HA; Nagatomo, T; Ozaki, M | 1 |
| Eguchi, M; Hase, M; Hashimoto, A; Kokubu, N; Miura, T; Nagao, K; Nakata, T; Shimamoto, K; Tsuchihashi, K; Tsuzuki, M; Ura, N; Wakabayashi, C; Wakabayashi, T; Yuda, S | 1 |
| Nonogaki, K; Nozue, K; Oka, Y | 1 |
| Enyo, Y; Hashizume, H; Inomata, Y; Kawakami, M; Okada, M; Yoshida, M | 1 |
| Chayama, K; Goto, C; Higashi, Y; Miyazaki, M; Orihashi, K; Sanada, H; Sueda, T; Yoshizumi, M | 1 |
| Kondo, K; Nishimaru, K; Ozaki, Y; Satoh, K; Uchiyama, S | 1 |
| Kikuchi, S; Konno, S; Sekiguchi, M | 1 |
| Arakawa, S; Fujimoto, S; Haruna, Y; Kashihara, N; Kobayashi, S; Komai, N; Namikoshi, T; Sasaki, T; Satoh, M; Tomita, N | 1 |
| Hattori, K; Itoh, T; Kajikuri, J; Kodama, A; Komori, K; Yamanouchi, D | 1 |
| Hamaue, N; Hirafuji, M; Iizuka, K; Machida, T; Tsuji, M | 1 |
| Aly, SA; Bhuiyan, MA; Hossain, M; Nagatomo, T; Nakamura, T | 1 |
| Itoh, T; Kajikuri, J; Kodama, A; Komori, K | 1 |
| Chayama, K; Goto, C; Higashi, Y; Miyazaki, M; Sanada, H; Sueda, T | 1 |
| Bi, S; Jin, HB; Li, J; Su, Y; Sun, YM | 1 |
| Ajjala, D; Kandikere, V; Mudigonda, K; Nirogi, R; Suraneni, R; Thoddi, P | 1 |
| Chung, WY; Kim, MA; Kim, SH; Park, K; Park, YB; Seo, JB; Zo, JH | 1 |
| Itoh, T; Kajikuri, J | 1 |
| Furukawa, F; Ikeda, T; Kanazawa, N; Uede, K; Yoshimasu, T | 1 |
| Chen, L; Dhalla, NS; Elimban, V; Ji, L; Xu, YJ; Zhang, M | 1 |
| Nagai, H; Nakagawa, H; Niki, H; Nishikawa, M; Yamada, K | 1 |
| Bhuiyan, MA; Hossain, M; Ishiguro, M; Muntasir, HA; Nagatomo, T; Rashid, M; Sugihara, T | 1 |
| Hidaka, S; Ishioka, K; Isshiki, R; Iwagami, M; Kobayashi, S; Maesato, K; Mochida, Y; Moriya, H; Ohtake, T; Oka, M; Tsutsumi, D | 1 |
| Dong, X; Li, M; Li, YB; Lin, FZ; Mao, N; Su, Y; Xu, Y | 1 |
| Choi, HS; Jun, DW; Kim, DC; Kim, EK; Kwon, YI; Lee, HL; Lee, KN; Lee, OY; Yoon, BC | 1 |
| Ando, N; Harada, H; Kitagawa, Y; Matsubara, K; Matsumoto, K; Obara, H; Watada, S | 1 |
| Coyner, AS; Datta, S; Gale, MJ; Ku, C; Nicholson, A; Pennesi, ME; Regis, D; Ryals, RC; Sinha, W; Tullis, BE; Wen, Y; Yang, P | 1 |
| Ariyama, Y; Deushi, M; Kataoka, H; Nitta, K; Osaka, M; Yoshida, M | 1 |
| Fan, FL; Geng, J; He, S; Liu, Y; Ma, Q; Meng, Y; Tian, H; Tian, HY; Zhang, D; Zhang, JB | 1 |
| Chun, EJ; Han, SJ; Hur, JH; Jang, HC; Kang, DK; Kim, HJ; Kim, KM; Lee, DH; Lee, JE; Lim, S; Min, SH; Oh, TJ | 1 |
| Distler, JHW; Ensminger, SM; Gocht, A; Heim, C; Ramsperger-Gleixner, M; Spriewald, B; Weyand, M | 1 |
| Aoyama, T; Katsuyama, M; Kawano, Y; Mano, Y; Mori, A; Nagata, M; Nakamatsu, S; Negishi, K; Obana, M; Sakamoto, N; Shimada, S | 1 |
| Abd El Latif, HA; El Yamani, M; Fouad Shalaby, MA; Galal, MA; Kamal, S; Masaood, R; Sindi, I | 1 |
| Fajkis-Zajaczkowska, N; Jaromin, A; Kolaczkowski, M; Kubacka, M; Marcinkowska, M; Zagorska, A | 1 |
1 review(s) available for sarpogrelate and mdl 100907
| Article | Year |
|---|---|
Therapeutic potentials of sarpogrelate in cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Serotonin 5-HT2 Receptor Antagonists; Succinates | 2004 |
10 trial(s) available for sarpogrelate and mdl 100907
| Article | Year |
|---|---|
Sarpogrelate, a 5-HT2 receptor blocker, may have a preconditioning-like effect in patients with coronary artery disease.
Topics: Blood Pressure; Collateral Circulation; Coronary Disease; Electrocardiography; Female; Heart Rate; Hemodynamics; Humans; Ischemic Preconditioning, Myocardial; Male; Middle Aged; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Succinates | 2004 |
New treatment of lumbar disc herniation involving 5-hydroxytryptamine2A receptor inhibitor: a randomized controlled trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Autonomic Nerve Block; Diclofenac; Epidural Space; Female; Humans; Intervertebral Disc Displacement; Low Back Pain; Lumbar Vertebrae; Male; Pain Measurement; Prospective Studies; Sciatica; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Succinates | 2005 |
Sarpogrelate, a 5-hT2A receptor antagonist in intermittent claudication. A phase II European study.
Topics: Adult; Aged; Double-Blind Method; Europe; Exercise Test; Female; Humans; Intermittent Claudication; Lower Extremity; Male; Middle Aged; Receptor, Serotonin, 5-HT2A; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Succinates; Treatment Outcome; Walking | 2006 |
Persistent insulin-sensitizing effects of sarpogrelate hydrochloride, a serotonin 2A receptor antagonist, in patients with peripheral arterial disease.
Topics: Adiponectin; Aged; Aged, 80 and over; Atherosclerosis; Blood Pressure; Female; Homeostasis; Humans; Insulin Resistance; Male; Middle Aged; Peripheral Vascular Diseases; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Succinates | 2006 |
Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Arterial Occlusive Diseases; Biomarkers; Endothelium, Vascular; Female; Follow-Up Studies; Forearm; Humans; Hyperemia; Leg; Male; Nitroglycerin; Peripheral Vascular Diseases; Regional Blood Flow; Research Design; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Succinates; Time Factors; Treatment Outcome; Vasodilator Agents | 2007 |
Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study.
Topics: Administration, Oral; Aged; Blood Platelets; Brain Ischemia; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Epinephrine; Female; Humans; Japan; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Receptor, Serotonin, 5-HT2A; Serotonin; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Stroke; Succinates; Time Factors; Treatment Outcome | 2007 |
Sarpogrelate hydrochloride, a selective 5-hydroxytryptamine(2A) antagonist, augments autologous bone marrow mononuclear cell implantation-induced improvement in endothelium-dependent vasodilation in patients with critical limb ischemia.
Topics: Acetylcholine; Aged; Bone Marrow Transplantation; Combined Modality Therapy; Endothelium, Vascular; Female; Follow-Up Studies; Humans; Ischemia; Leg; Male; Middle Aged; Nitroprusside; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Succinates; Transplantation, Autologous; Vasodilator Agents | 2010 |
The prevention of contrast induced nephropathy by sarpogrelate in patients with chronic kidney disease: a study protocol for a prospective randomized controlled clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Clinical Protocols; Contrast Media; Humans; Kidney Diseases; Middle Aged; Prospective Studies; Research Design; Serotonin 5-HT2 Receptor Antagonists; Succinates; Young Adult | 2010 |
Sarpogrelate hydrochloride, a selective 5-HT(2A) receptor antagonist, improves skin perfusion pressure of the lower extremities in hemodialysis patients with peripheral arterial disease.
Topics: Aged; Blood Pressure; Female; Follow-Up Studies; Humans; Kidney Failure, Chronic; Lower Extremity; Male; Oxidative Stress; Oxygen Consumption; Peripheral Arterial Disease; Prospective Studies; Renal Dialysis; Serotonin 5-HT2 Receptor Antagonists; Skin; Succinates | 2013 |
Effect of sarpogrelate, a selective 5-HT
Topics: Adult; Aged; Ankle Brachial Index; Anti-Inflammatory Agents; Aspirin; Biomarkers; Computed Tomography Angiography; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Coronary Vessels; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Insulin Resistance; Male; Middle Aged; Multidetector Computed Tomography; Plaque, Atherosclerotic; Platelet Aggregation Inhibitors; Pulse Wave Analysis; Republic of Korea; Serotonin 5-HT2 Receptor Antagonists; Severity of Illness Index; Succinates; Time Factors; Treatment Outcome; Vascular Calcification | 2017 |
35 other study(ies) available for sarpogrelate and mdl 100907
| Article | Year |
|---|---|
Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats.
Topics: Animals; Endothelium, Vascular; Hypertension, Pulmonary; Lung; Male; Monocrotaline; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; P-Selectin; Rats; Rats, Sprague-Dawley; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Succinates; Survival Rate | 2003 |
Selective blockade of serotonin 5-HT2A receptor increases coronary blood flow via augmented cardiac nitric oxide release through 5-HT1B receptor in hypoperfused canine hearts.
Topics: Animals; Dogs; Heart; Immunohistochemistry; Myocardium; Nitric Oxide; Receptor, Serotonin, 5-HT1B; Serotonin; Serotonin 5-HT2 Receptor Antagonists; Succinates; Time Factors | 2004 |
Effects of a 5-HT2A receptor antagonist, sarpogrelate on thermal or inflammatory pain.
Topics: Analgesics; Animals; Behavior, Animal; Dose-Response Relationship, Drug; Hyperalgesia; Inflammation; Injections, Intraperitoneal; Injections, Spinal; Male; Pain; Pain Measurement; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Serotonin; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Serotonin Receptor Agonists; Succinates; Time Factors | 2005 |
Protective effects of sarpogrelate, a 5-HT2A antagonist, against postischemic myocardial dysfunction in guinea-pig hearts.
Topics: Animals; Calcium; Calcium Signaling; Cardiotonic Agents; Free Radical Scavengers; Free Radicals; Fura-2; Guinea Pigs; In Vitro Techniques; Mitochondria, Heart; Myocardial Contraction; Myocardial Reperfusion; Myocardial Reperfusion Injury; Nitric Oxide; Phosphorus; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Succinates | 2005 |
Contribution of the peripheral 5-HT 2A receptor to mechanical hyperalgesia in a rat model of neuropathic pain.
Topics: Animals; Binding Sites; Binding, Competitive; Denervation; Disease Models, Animal; Drug Interactions; Hyperalgesia; Ketanserin; Ligation; Male; Neuralgia; Pain Threshold; Peripheral Nerves; Peripheral Nervous System Diseases; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Sciatic Neuropathy; Sensory Receptor Cells; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Serotonin Receptor Agonists; Succinates | 2005 |
5-HT2A receptor antagonist increases circulating adiponectin in patients with type 2 diabetes.
Topics: Adiponectin; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Female; Humans; Male; Middle Aged; Platelet Activation; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Succinates | 2005 |
A new method for assessment of an anti-5HT(2A) agent, sarpogrelate hydrochloride, on platelet aggregation.
Topics: Arginine; Epinephrine; Humans; In Vitro Techniques; Pipecolic Acids; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Serotonin; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Succinates; Sulfonamides | 2006 |
Peripheral 5-HT2A receptor antagonism attenuates primary thermal hyperalgesia and secondary mechanical allodynia after thermal injury in rats.
Topics: Animals; Burns; Dose-Response Relationship, Drug; Hot Temperature; Hyperalgesia; Male; Pain Threshold; Physical Stimulation; Rats; Rats, Wistar; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Succinates; Touch; Treatment Outcome | 2006 |
Inverse agonist activity of sarpogrelate, a selective 5-HT2A-receptor antagonist, at the constitutively active human 5-HT2A receptor.
Topics: Binding, Competitive; Cell Line; Cloning, Molecular; Dose-Response Relationship, Drug; Humans; Ligands; Mutation; Radioligand Assay; Receptor, Serotonin, 5-HT2A; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Serotonin Receptor Agonists; Succinates; Transfection | 2006 |
Increased hypothalamic 5-HT2A receptor gene expression and effects of pharmacologic 5-HT2A receptor inactivation in obese Ay mice.
Topics: Adiponectin; Animals; Appetite; Body Weight; Eating; Gene Expression; Hypothalamus; Male; Mice; Mice, Obese; Nerve Tissue Proteins; Neuropeptide Y; Obesity; Pro-Opiomelanocortin; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Receptors, Corticotropin-Releasing Hormone; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Succinates | 2006 |
Sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, attenuates neurogenic pain induced by nucleus pulposus in rats.
Topics: Animals; Intervertebral Disc; Intervertebral Disc Displacement; Lumbar Vertebrae; Pain Measurement; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Succinates | 2007 |
The effects of a 5-HT2A receptor antagonist on blood flow in lumbar disc herniation: application of nucleus pulposus in a canine model.
Topics: Animals; Blood Vessels; Disease Models, Animal; Dogs; Female; Intervertebral Disc; Intervertebral Disc Displacement; Lumbar Vertebrae; Radiculopathy; Regional Blood Flow; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Spinal Nerve Roots; Succinates | 2008 |
Blockade of serotonin 2A receptor improves glomerular endothelial function in rats with streptozotocin-induced diabetic nephropathy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adiponectin; Albuminuria; Animals; Blood Platelets; Deoxyguanosine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endothelium, Vascular; Immunohistochemistry; Kidney Glomerulus; Male; Nitric Oxide; Nitric Oxide Synthase; Platelet Aggregation; Rats; Rats, Wistar; Reactive Oxygen Species; Receptor, Serotonin, 5-HT2A; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Succinates; Time Factors | 2008 |
Sarpogrelate hydrochloride reduced intimal hyperplasia in experimental rabbit vein graft.
Topics: Acetylcholine; Administration, Oral; Animals; Carotid Arteries; Cell Proliferation; Endothelium, Vascular; Enzyme Inhibitors; Hyperplasia; Jugular Veins; Male; Models, Animal; Nitric Oxide; Nitric Oxide Synthase Type III; Nitroarginine; Rabbits; Receptor, Serotonin, 5-HT2A; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Succinates; Superoxides; Tunica Intima; Vasodilation; Vasodilator Agents | 2009 |
Acute effects of sarpogrelate, a 5-HT2A receptor antagonist on cytokine production in endotoxin shock model of rats.
Topics: Animals; Cytokines; Disease Models, Animal; Hemodynamics; Lung; Male; Rats; Rats, Sprague-Dawley; Respiration; Serotonin 5-HT2 Receptor Antagonists; Shock, Septic; Succinates; Survival Rate | 2009 |
Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice.
Topics: Abdominal Fat; Adipocytes; Animals; Blood Glucose; Cell Count; Diabetes Mellitus, Type 2; Disease Models, Animal; Drinking; Drug Therapy, Combination; Eating; Hypoglycemic Agents; Insulin; Leptin; Lipids; Male; Mice; Pioglitazone; Serotonin 5-HT2 Receptor Antagonists; Succinates; Thiazolidinediones | 2009 |
Assessment of binding affinity to 5-hydroxytryptamine 2A (5-HT2A) receptor and inverse agonist activity of naftidrofuryl: comparison with those of sarpogrelate.
Topics: Cell Line; Drug Inverse Agonism; Humans; Mutation; Nafronyl; Protein Binding; Protein Transport; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Succinates; Vasodilator Agents | 2009 |
Chronic treatment of hydroxytryptamine type 2a receptor antagonist sarpogrelate hydrochloride modulates the vasoreactivity of serotonin in experimental rabbit vein grafts.
Topics: Animals; Benzamides; Carotid Artery, Common; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme Inhibitors; Graft Occlusion, Vascular; Jugular Veins; Male; Muscle, Smooth, Vascular; Nitric Oxide; Nitric Oxide Synthase; Nitroarginine; Pyridines; Rabbits; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT2A; Serotonin; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Succinates; Vasoconstriction | 2009 |
Sarpogrelate protects against high glucose-induced endothelial dysfunction and oxidative stress.
Topics: Animals; Aorta, Thoracic; Endothelium, Vascular; Female; Free Radical Scavengers; Glucose; Male; Oxidative Stress; Rats; Rats, Sprague-Dawley; Serotonin 5-HT2 Receptor Antagonists; Succinates; Vasodilation | 2011 |
Liquid chromatography tandem mass spectrometry method for the quantification of sarpogrelate, a selective 5-HT(₂A) receptor antagonist, in plasma: application to a pre-clinical pharmacokinetic study.
Topics: Animals; Chromatography, High Pressure Liquid; Drug Evaluation, Preclinical; Humans; Male; Rats; Rats, Wistar; Serotonin 5-HT2 Receptor Antagonists; Succinates; Tandem Mass Spectrometry | 2010 |
Characteristics of the actions by which 5-HT affects electrical and mechanical activities in rabbit jugular vein.
Topics: Adenine; Animals; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Dinoprost; Endothelium, Vascular; Glyburide; Immunohistochemistry; Isometric Contraction; Jugular Veins; Male; Membrane Potentials; Muscle, Smooth, Vascular; Nitric Oxide; Phenols; Rabbits; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Serotonin; Serotonin 5-HT2 Receptor Antagonists; Succinates; Sulfonamides; Vasodilation | 2011 |
Effects of sarpogrelate hydrochloride on skin ulcers and quality of life in patients with systemic sclerosis.
Topics: Aged; Female; Humans; Male; Middle Aged; Quality of Life; Scleroderma, Diffuse; Scleroderma, Limited; Scleroderma, Systemic; Serotonin 5-HT2 Receptor Antagonists; Skin Ulcer; Succinates | 2012 |
Suppression of high lipid diet induced by atherosclerosis sarpogrelate.
Topics: Animals; Aorta, Thoracic; Atherosclerosis; Blood Viscosity; Cholesterol, Dietary; Diet, High-Fat; Foam Cells; Male; Malondialdehyde; Oxidative Stress; Plaque, Atherosclerotic; Platelet Aggregation Inhibitors; Rabbits; Serotonin 5-HT2 Receptor Antagonists; Succinates; Superoxide Dismutase; Triglycerides | 2012 |
Serotonin potentiates high-glucose-induced endothelial injury: the role of serotonin and 5-HT(2A) receptors in promoting thrombosis in diabetes.
Topics: Animals; Aspirin; Cells, Cultured; Cilostazol; Diabetes Mellitus, Experimental; Fibrinolytic Agents; Glucose; Human Umbilical Vein Endothelial Cells; Humans; Male; Platelet Aggregation; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Serotonin; Serotonin 5-HT2 Receptor Antagonists; Succinates; Tetrazoles; Thrombosis; Vascular Cell Adhesion Molecule-1 | 2012 |
Mechanism of inverse agonist action of sarpogrelate at the constitutively active mutant of human 5-HT2A receptor revealed by molecular modeling.
Topics: HEK293 Cells; Humans; Models, Molecular; Mutation; Protein Structure, Secondary; Receptor, Serotonin, 5-HT2A; Serotonin 5-HT2 Receptor Antagonists; Succinates | 2012 |
Sarpogrelate inhibits the expression of ICAM-1 and monocyte-endothelial adhesion induced by high glucose in human endothelial cells.
Topics: Cell Adhesion; Cells, Cultured; Coculture Techniques; Gene Expression; Glucose; Human Umbilical Vein Endothelial Cells; Humans; Intercellular Adhesion Molecule-1; Leukocytes, Mononuclear; Serotonin 5-HT2 Receptor Antagonists; Succinates; Superoxide Dismutase | 2013 |
5-HT2A receptor antagonists inhibit hepatic stellate cell activation and facilitate apoptosis.
Topics: Actins; Animals; Apoptosis; Cell Line; Cell Survival; Collagen Type I; Dose-Response Relationship, Drug; Hepatic Stellate Cells; Humans; Ketanserin; Liver Cirrhosis, Experimental; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Receptor, Serotonin, 5-HT2A; Ritanserin; RNA, Messenger; Serotonin 5-HT2 Receptor Antagonists; Smad2 Protein; Smad3 Protein; Succinates; Thioacetamide; Time Factors; Transforming Growth Factor beta; Wound Healing | 2013 |
Effect of sarpogrelate hydrochloride, a 5-hydroxytryptamine2 receptor antagonist, on allograft arteriosclerosis after aortic transplantation in rats.
Topics: Allografts; Animals; Aorta; Arteriosclerosis; Fibrinolytic Agents; Male; Organ Transplantation; Rats; Rats, Inbred Lew; Serotonin 5-HT2 Receptor Antagonists; Succinates | 2013 |
Sarpogrelate, a 5-HT2A Receptor Antagonist, Protects the Retina From Light-Induced Retinopathy.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Disease Models, Animal; Electroretinography; Injections, Intraperitoneal; Light; Mice; Mice, Inbred BALB C; Radiation Injuries, Experimental; Radiation-Protective Agents; Retina; Retinal Degeneration; Serotonin 5-HT2 Receptor Antagonists; Serotonin Receptor Agonists; Succinates; Tomography, Optical Coherence | 2015 |
Inhibitory Effect of Serotonin Antagonist on Leukocyte-Endothelial Interactions In Vivo and In Vitro.
Topics: Animals; Cell Adhesion; Cell Communication; Cell Line; Endothelial Cells; Endothelium, Vascular; Human Umbilical Vein Endothelial Cells; Inflammation; Leukocytes; Male; Mice, Inbred C57BL; Obesity; Serotonin 5-HT2 Receptor Antagonists; Succinates | 2016 |
The effects of the 5-HT2A receptor antagonist sarpogrelate hydrochloride on chronic hypoxic pulmonary hypertension in rats.
Topics: Animals; Apoptosis; Cell Proliferation; Chronic Disease; Hypertension, Pulmonary; Hypoxia; Male; Myocytes, Smooth Muscle; Premedication; Pulmonary Artery; Rats; Rats, Sprague-Dawley; Serotonin 5-HT2 Receptor Antagonists; Succinates | 2016 |
Effects of different serotonin receptor subtype antagonists on the development of cardiac allograft vasculopathy in murine aortic allografts.
Topics: Animals; Aorta; Cell Proliferation; Female; Graft Rejection; Heart Transplantation; Humans; Indoles; Lisuride; Male; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Models, Animal; Serotonin; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Succinates; Transendothelial and Transepithelial Migration; Transplantation, Homologous; Urea | 2018 |
Antiplatelet Effect of Mirtazapine via Co-blocking of the 5-HT
Topics: Administration, Oral; Adrenergic alpha-2 Receptor Antagonists; Animals; Blood Platelets; Epinephrine; Male; Mice; Mirtazapine; Models, Animal; Platelet Aggregation; Receptor, Serotonin, 5-HT2A; Serotonin; Serotonin 5-HT2 Receptor Antagonists; Succinates; Yohimbine | 2021 |
Therapeutic activity of sarpogrelate and dopamine D
Topics: Animals; Blood Glucose; Bromocriptine; Cabergoline; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dopamine Agonists; Drug Therapy, Combination; Isoenzymes; Kidney; L-Lactate Dehydrogenase; Male; Myocardial Infarction; Myocardium; Rats, Wistar; Serotonin 5-HT2 Receptor Antagonists; Succinates; Troponin I; Tumor Necrosis Factor-alpha | 2021 |
Exploring the antiplatelet activity of serotonin 5-HT
Topics: Animals; Cardiovascular Diseases; Humans; Isoxazoles; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Serotonin 5-HT2 Receptor Antagonists; Structure-Activity Relationship; Succinates; Vasoconstriction | 2022 |